Uromitexan Baxter



Indications and Reactions:

Role Indications Reactions
Primary
Product Used For Unknown Indication 28.8%
Drug Use For Unknown Indication 23.7%
Bone Sarcoma 5.1%
Desmoplastic Small Round Cell Tumour 3.4%
Metastatic Uterine Cancer 3.4%
Prophylaxis 3.4%
Sarcoma 3.4%
Systemic Lupus Erythematosus 3.4%
Acute Biphenotypic Leukaemia 2.8%
Chemotherapy 2.8%
Non-hodgkin's Lymphoma 2.8%
Prophylaxis Of Nausea And Vomiting 2.8%
Breast Cancer 2.3%
Ovarian Cancer 2.3%
Small Cell Lung Cancer Stage Unspecified 2.3%
Vomiting 2.3%
Burkitt's Lymphoma 1.7%
Analgesic Therapy 1.1%
Computerised Tomogram 1.1%
Endometrial Sarcoma 1.1%
Febrile Neutropenia 14.7%
Renal Failure 14.7%
Anaphylactic Reaction 8.8%
Encephalopathy 8.8%
Myelodysplastic Syndrome 8.8%
Toxic Encephalopathy 8.8%
Cystitis Haemorrhagic 5.9%
Nausea 5.9%
Chest Pain 2.9%
Face Oedema 2.9%
Hyperthermia 2.9%
Oropharyngeal Pain 2.9%
Pancytopenia 2.9%
Renal Tubular Atrophy 2.9%
Thrombocytopenia 2.9%
Vomiting 2.9%
Secondary
Product Used For Unknown Indication 23.4%
Drug Use For Unknown Indication 22.4%
Hodgkin's Disease 10.3%
Bone Sarcoma 8.1%
Diffuse Large B-cell Lymphoma 3.9%
Lymphoma 3.9%
Non-hodgkin's Lymphoma 3.8%
Breast Cancer 3.2%
Sarcoma 3.0%
Testis Cancer 2.8%
Vasculitis Cerebral 2.2%
B-cell Lymphoma Stage Iv 1.9%
Central Nervous System Lymphoma 1.6%
Leiomyosarcoma 1.6%
Microscopic Polyangiitis 1.6%
Prophylaxis 1.5%
Premedication 1.4%
Hodgkin's Disease Stage Iv 1.2%
Fluid Replacement 1.1%
Liposarcoma 1.1%
Vomiting 24.7%
Fatigue 9.9%
Renal Failure 8.6%
Glomerular Filtration Rate Decreased 7.4%
Cytolytic Hepatitis 6.2%
Encephalopathy 3.7%
Erythema 3.7%
Pyrexia 3.7%
Renal Tubular Disorder 3.7%
Toxic Epidermal Necrolysis 3.7%
Angioedema 2.5%
Atrial Flutter 2.5%
Bone Marrow Failure 2.5%
Cerebral Infarction 2.5%
Confusional State 2.5%
Hypotension 2.5%
Interstitial Lung Disease 2.5%
Mucosal Inflammation 2.5%
Neurotoxicity 2.5%
Neutropenia 2.5%
Concomitant
Rhabdomyosarcoma 25.8%
Chemotherapy 22.6%
Drug Use For Unknown Indication 19.4%
Diffuse Large B-cell Lymphoma Stage Ii 12.9%
Pyrexia 12.9%
Nausea 6.5%
Urine Output Decreased 66.7%
Paraesthesia 33.3%